tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ONCT Stock Latest News

Oncternal completes enrollment, dosing in Phase 1/2 study of ONCT-534
The FlyOncternal completes enrollment, dosing in Phase 1/2 study of ONCT-534
4d ago
ONCT
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
PremiumPress Releases
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
8d ago
ONCT
Oncternal: Enrollment complete in 1/2 Study of ONCT-534 to treat R/R PCa
PremiumThe Fly
Oncternal: Enrollment complete in 1/2 Study of ONCT-534 to treat R/R PCa
2M ago
ONCT
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
PremiumPress Releases
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
2M ago
ONCT
Oncternal Therapeutics price target lowered to $19 from $28 at H.C. Wainwright
PremiumThe Fly
Oncternal Therapeutics price target lowered to $19 from $28 at H.C. Wainwright
2M ago
ONCT
Oncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)
PremiumThe FlyOncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)
2M ago
ONCT
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
PremiumPress Releases
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
2M ago
ONCT
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
PremiumThe Fly
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
3M ago
ONCT
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3M ago
ONCT
ONCT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ONCT Earnings this Week: How Will it Perform?
3M ago
ONCT
Oncternal announces first patient dosed in fourth cohort of study of ONCT-534
PremiumThe Fly
Oncternal announces first patient dosed in fourth cohort of study of ONCT-534
3M ago
ONCT
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
PremiumPress Releases
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
3M ago
ONCT
Oncternal Therapeutics price target lowered to $28 from $30 at H.C. Wainwright
PremiumThe FlyOncternal Therapeutics price target lowered to $28 from $30 at H.C. Wainwright
3M ago
ONCT
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
PremiumPress Releases
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
4M ago
ONCT
Oncternal Therapeutics files $250M mixed securities shelf
PremiumThe Fly
Oncternal Therapeutics files $250M mixed securities shelf
4M ago
ONCT
Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
PremiumThe Fly
Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
4M ago
ONCT
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4M ago
ONCT
Oncternal Therapeutics (ONCT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Oncternal Therapeutics (ONCT) Q4 Earnings Cheat Sheet
5M ago
ONCT
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
PremiumPress Releases
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
5M ago
ONCT
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
6M ago
ONCT
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
PremiumThe Fly
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
6M ago
ONCT
Oncternal Therapeutics target adjusted to $30 from $2 at H.C. Wainwright
PremiumThe Fly
Oncternal Therapeutics target adjusted to $30 from $2 at H.C. Wainwright
6M ago
ONCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >